At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 318 enrolled
Drug / intervention
Mexidol +1 moredrug
Likely dose
Mexidol 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International Multicentre Randomized, Double-blind, Placebo-controlled Adaptive Design Clinical Trial to Evaluate the Safety and Efficacy of Sequential Therapy With Mexidol® Solution for Intravenous and Intramuscular Administration, 50 mg/ml (RPC PHARMASOFT LLC, Russia) and Mexidol® FORTE 250 Film-coated Tablets, 250 mg (RPC PHARMASOFT LLC, Russia) in Patients With Chronic Cerebral Ischemia (MEMO)
In Brief
A Phase 3 clinical trial evaluating Mexidol and Placebo for Chronic Cerebral Ischemia. Completed, enrolled 318 participants across 14 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cerebral Ischemia
CountriesRussia, Uzbekistan
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartNov 2019
Primary CompletionDec 2020
First PostedFeb 2025
TodayJul 2026
First PostedFeb 19, 2025
Enrollment StartNov 5, 2019
Primary CompletionDec 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 1.4 years ago
Interventions
Mexidoldrug
50 mg/ml IV solution, 250 mg tablets
Placebodrug
Placebo IV solution, Placebo tablets